STOCK TITAN

[Form 4] ClearPoint Neuro, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

ClearPoint Neuro, Inc. (CLPT) reported an insider issuance to director Pascal E. R. Girin: on 10/01/2025 the company issued 315 shares of common stock at a price equal to the closing market price on 9/30/2025, $21.79, as payment of fees under the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan and the Non-Employee Director Compensation Plan. Following the issuance, the reporting person beneficially owns 96,949 shares directly. The Form 4 was signed by an attorney under power of attorney and filed on 10/02/2025.

ClearPoint Neuro, Inc. (CLPT) ha riferito un’emissione interna a favore del direttore Pascal E. R. Girin: il 10/01/2025 la società ha emesso 315 azioni ordinarie a un prezzo pari al prezzo di chiusura di mercato del 9/30/2025, $21.79, come pagamento di onorari ai sensi del Sixth Amended and Restated 2013 Incentive Compensation Plan della società e del Non-Employee Director Compensation Plan. Dopo l’emissione, la persona che segnala detiene direttamente 96,949 azioni. Il Form 4 è stato firmato da un avvocato in base a una procura e presentato il 10/02/2025.

ClearPoint Neuro, Inc. (CLPT) informó una emisión interna al director Pascal E. R. Girin: el 10/01/2025 la empresa emitió 315 acciones comunes a un precio igual al del cierre del mercado el 9/30/2025, $21.79, como pago de honorarios conforme al Sixth Amended and Restated 2013 Incentive Compensation Plan de la emisora y al Non-Employee Director Compensation Plan. Tras la emisión, la persona reportante posee beneficiosamente directamente 96,949 acciones. El Form 4 fue firmado por un abogado mediante poder y presentado el 10/02/2025.

ClearPoint Neuro, Inc. (CLPT)는 Pascal E. R. Girin 이사에 대한 내부 발행을 보고했습니다: 2025-10-01 회사는 315 주의 보통주를 9/30/2025의 종가와 동일한 가격으로 발행했으며 $21.79로 발행 수수료를 상환하기 위한 것으로, 발행자의 Sixth Amended and Restated 2013 Incentive Compensation Plan 및 Non-Employee Director Compensation Plan에 따른 것입니다. 발행 후 보고자는 직접적으로 96,949 주를 지분 소유합니다. Form 4는 위임장을 가진 변호사에 의해 서명되어 2025-10-02에 제출되었습니다.

ClearPoint Neuro, Inc. (CLPT) a annoncé une emission interne au profit du directeur Pascal E. R. Girin : le 10/01/2025, la société a sié emise 315 actions ordinaires à un prix égal au cours de clôture du marché le 9/30/2025, $21.79, en paiement des frais en vertu du Sixth Amended and Restated 2013 Incentive Compensation Plan de l’emetteur et du Non-Employee Director Compensation Plan. Suite à l’émission, la personne qui déclare détient directement 96,949 actions. Le Form 4 a été signé par un avocat sous procuration et déposé le 10/02/2025.

ClearPoint Neuro, Inc. (CLPT) meldete eine Insider-Emission zugunsten des Direktors Pascal E. R. Girin: Am 10/01/2025 emittierte das Unternehmen 315 Stammaktien zu einem Preis, der dem Schlusskurs des Marktes am 9/30/2025 entspricht, $21.79, als Bezahlung von Gebühren gemäß dem Sixth Amended and Restated 2013 Incentive Compensation Plan der Emittentin und dem Non-Employee Director Compensation Plan. Nach der Emission besitzt die meldende Person direkt 96,949 Aktien. Das Formular 4 wurde von einem Bevollmächtigten unter Vollmacht unterzeichnet und am 10/02/2025 eingereicht.

ClearPoint Neuro, Inc. (CLPT) أبلغت عن إصدار داخلي للمُدير باسكال إ. ر. جيرين: في 10/01/2025 أصدرت الشركة 315 سهماً عادياً بسعر يساوي سعر الإغلاق في السوق في 9/30/2025، $21.79، كدفع للرسوم وفقاً للخطة السادسة المعدلة والمعاد صياغتها لعام 2013 لتعويض الحوافز وخطة تعويض عضو مجلس الإدارة غير التنفيذي. عقب الإصدار، يملك مقدِّم التقرير فائدة مباشرة 96,949 سهماً. تم توقيع النموذج Form 4 من قبل محامٍ بموجب توكيل وتقديمه في 10/02/2025.

ClearPoint Neuro, Inc. (CLPT) 公布了对董事 Pascal E. R. Girin 的内部发行:在 2025/10/01 公司以等于 9/30/2025 的收盘价 $21.79 向其发行了 315 份普通股,作为根据发行人第六次修订并重新表述的2013年激励补偿计划以及非雇员董事补偿计划支付的费用。发行后,申报人直接受益持有 96,949 股。Form 4 由律师代理签署并于 2025/10/02 提交。

Positive
  • 315 shares issued were paid as director compensation under the company's 2013 Incentive Compensation Plan
  • Reporting person now directly holds 96,949 shares following the issuance
Negative
  • None.

ClearPoint Neuro, Inc. (CLPT) ha riferito un’emissione interna a favore del direttore Pascal E. R. Girin: il 10/01/2025 la società ha emesso 315 azioni ordinarie a un prezzo pari al prezzo di chiusura di mercato del 9/30/2025, $21.79, come pagamento di onorari ai sensi del Sixth Amended and Restated 2013 Incentive Compensation Plan della società e del Non-Employee Director Compensation Plan. Dopo l’emissione, la persona che segnala detiene direttamente 96,949 azioni. Il Form 4 è stato firmato da un avvocato in base a una procura e presentato il 10/02/2025.

ClearPoint Neuro, Inc. (CLPT) informó una emisión interna al director Pascal E. R. Girin: el 10/01/2025 la empresa emitió 315 acciones comunes a un precio igual al del cierre del mercado el 9/30/2025, $21.79, como pago de honorarios conforme al Sixth Amended and Restated 2013 Incentive Compensation Plan de la emisora y al Non-Employee Director Compensation Plan. Tras la emisión, la persona reportante posee beneficiosamente directamente 96,949 acciones. El Form 4 fue firmado por un abogado mediante poder y presentado el 10/02/2025.

ClearPoint Neuro, Inc. (CLPT)는 Pascal E. R. Girin 이사에 대한 내부 발행을 보고했습니다: 2025-10-01 회사는 315 주의 보통주를 9/30/2025의 종가와 동일한 가격으로 발행했으며 $21.79로 발행 수수료를 상환하기 위한 것으로, 발행자의 Sixth Amended and Restated 2013 Incentive Compensation Plan 및 Non-Employee Director Compensation Plan에 따른 것입니다. 발행 후 보고자는 직접적으로 96,949 주를 지분 소유합니다. Form 4는 위임장을 가진 변호사에 의해 서명되어 2025-10-02에 제출되었습니다.

ClearPoint Neuro, Inc. (CLPT) a annoncé une emission interne au profit du directeur Pascal E. R. Girin : le 10/01/2025, la société a sié emise 315 actions ordinaires à un prix égal au cours de clôture du marché le 9/30/2025, $21.79, en paiement des frais en vertu du Sixth Amended and Restated 2013 Incentive Compensation Plan de l’emetteur et du Non-Employee Director Compensation Plan. Suite à l’émission, la personne qui déclare détient directement 96,949 actions. Le Form 4 a été signé par un avocat sous procuration et déposé le 10/02/2025.

ClearPoint Neuro, Inc. (CLPT) meldete eine Insider-Emission zugunsten des Direktors Pascal E. R. Girin: Am 10/01/2025 emittierte das Unternehmen 315 Stammaktien zu einem Preis, der dem Schlusskurs des Marktes am 9/30/2025 entspricht, $21.79, als Bezahlung von Gebühren gemäß dem Sixth Amended and Restated 2013 Incentive Compensation Plan der Emittentin und dem Non-Employee Director Compensation Plan. Nach der Emission besitzt die meldende Person direkt 96,949 Aktien. Das Formular 4 wurde von einem Bevollmächtigten unter Vollmacht unterzeichnet und am 10/02/2025 eingereicht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Girin Pascal E R

(Last) (First) (Middle)
C/O CLEARPOINT NEURO, INC.
120 S. SIERRA AVE., SUITE 100

(Street)
SOLANA BEACH CA 92075

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 A 315 A $21.79(1) 96,949 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025.
/s/ Danilo D'Alessandro, by Power of Attorney for Pascal E. R. Girin 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction was reported for ClearPoint Neuro (CLPT)?

The Form 4 reports issuance of 315 shares of common stock to director Pascal E. R. Girin on 10/01/2025.

At what price were the shares issued to the director?

The shares were issued at the issuer's closing common stock price on 9/30/2025, which was $21.79 per share.

Why were the shares issued to the reporting person?

The shares were issued as payment of fees owed under the issuer's Non-Employee Director Compensation Plan, as amended and restated.

How many shares does the reporting person own after the transaction?

After the issuance, the reporting person beneficially owns 96,949 shares (direct ownership).

Who signed the Form 4 filing?

The Form 4 was signed by Danilo D'Alessandro by power of attorney for Pascal E. R. Girin and dated 10/02/2025.
Clearpoint Neuro Inc

NASDAQ:CLPT

CLPT Rankings

CLPT Latest News

CLPT Latest SEC Filings

CLPT Stock Data

594.42M
26.05M
8.19%
38.99%
8.25%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SOLANA BEACH